Summary of COVID-19 acebilustat studies
Studies
Meta Analysis
Hide extended summaries
120 patient acebilustat early treatment RCT: 80% lower progression (p=0.21), 67% worse recovery (p=0.07), and 6% improved viral clearance.
RCT 120 outpatients showing no significant difference in time to sustained symptom resolution or viral clearance with acebilustat treatment. Subgroup analyses showed consistent patterns of longer symptom duration in treated participants.
Mar 2023, Clinical Infectious Diseases, https://academic.oup.com/cid/article/77/2/186/7095671, https://c19p.org/levitt
120 patient acebilustat early treatment RCT: 80% lower progression (p=0.21), 67% worse recovery (p=0.07), and 6% improved viral clearance.
RCT 120 outpatients showing no significant difference in time to sustained symptom resolution or viral clearance with acebilustat treatment. Subgroup analyses showed consistent patterns of longer symptom duration in treated participants.
Mar 2023, Clinical Infectious Diseases, https://academic.oup.com/cid/article/77/2/186/7095671, https://c19p.org/levitt
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.